The UK and US have agreed to a key trade agreement that will guarantee zero duties on British drug products being sold in the American market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has pledged to raise spending on drugs through the public health system. This commitment secures that tariffs on these crucial products will be held at nothing for a duration of the next three years.
This development follows earlier threats to significantly raise duties on patented drug imports, with increases mentioned as high as 100%.
"This arrangement between the UK bolsters the global environment for cutting-edge drugs and introduces long-overdue fairness to transatlantic medicine commerce," a statement declared.
Economic Significance
Pharmaceuticals constitute one of the the United Kingdom's biggest export categories to the America, which is clearly the primary buyer for large companies like GSK and AstraZeneca.
Statistics indicate that in the year leading up to September, the UK exported medicines totaling £11.1bn to the US. This figure accounted for nearly one-fifth of British export trade in that period.
"This guarantee secures work, stimulates funding and sets the stage for the UK to become a global hub for medical research," a minister stated.
Key UK Commitments
The agreement includes several specific changes from the UK:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new therapies to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a target to double total health service expenditure on medicines from 0.3% of GDP to 0.6 percent over the next decade.
- Payback Limit: The amount manufacturers must refund to the NHS to control costs will be limited at fifteen percent. Last year, rebates were more than twenty percent.
Industry Background
The deal follows a long-running row between the drug companies and the ministers over spending levels and approval rates.
These tensions were heightened by arguments that US patients were paying several times more for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several significant manufacturing plans in the UK have been halted or scrapped, while multi-billion-dollar investments have been pledged toward American operations.
The Science Minister acknowledged that the NHS needed to invest a greater share on treatments, noting that its budget allocation on drugs had decreased as a percentage of its total funding over the past decade.
